Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Accelerate Diagnostics's Cyclically Adjusted PS Ratio or its related term are showing as below:
MEX:AXDX's Cyclically Adjusted PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.2 * Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Accelerate Diagnostics's adjusted revenue per share data for the three months ended in Dec. 2024 was MXN2.330. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN24.53 for the trailing ten years ended in Dec. 2024.
Shiller PE for Stocks: The True Measure of Stock Valuation
Accelerate Diagnostics (MEX:AXDX) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Accelerate Diagnostics Cyclically Adjusted PS Ratio Related Terms
Accelerate Diagnostics Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Accelerate Diagnostics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics Cyclically Adjusted PS Ratio Chart
MEX:AXDX vs MSIU, BIOLQ, AFIB: Cyclically Adjusted PS Ratio Comparison
For the Medical Devices subindustry, Accelerate Diagnostics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accelerate Diagnostics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's Cyclically Adjusted PS Ratio falls into.
Accelerate Diagnostics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 0.07 mean?
Accelerate Diagnostics (MEX:AXDX) has a Cyclically Adjusted PS Ratio of 0.07 as of Sep. 09, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Cyclically Adjusted PS Ratio too high?
Accelerate Diagnostics' current Cyclically Adjusted PS Ratio is 0.07. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.20. Accelerate Diagnostics' value of 0.07 is 96.8% below this industry median. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Cyclically Adjusted PS Ratio compare to MSIU and BIOLQ?
Accelerate Diagnostics' Cyclically Adjusted PS Ratio of 0.07 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cyclically Adjusted PS Ratio is 2.20. Accelerate Diagnostics' value of 0.07 is 96.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.20, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accelerate Diagnostics's current Cyclically Adjusted PS Ratio of 0.07 is 96.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Accelerate Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accelerate Diagnostics's current Cyclically Adjusted PS Ratio is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Cyclically Adjusted PS Ratio of 0.07. The current Cyclically Adjusted PS Ratio is 0.07 and 96.8% below the Medical Devices & Instruments industry median of 2.20. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Cyclically Adjusted PS Ratio is 0.07 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score
Get the complete analysis for MEX:AXDX
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AXDX has been successfully added to your 
